JP2015516412A - 局所麻酔薬のデポー製剤及びその調製方法 - Google Patents

局所麻酔薬のデポー製剤及びその調製方法 Download PDF

Info

Publication number
JP2015516412A
JP2015516412A JP2015510944A JP2015510944A JP2015516412A JP 2015516412 A JP2015516412 A JP 2015516412A JP 2015510944 A JP2015510944 A JP 2015510944A JP 2015510944 A JP2015510944 A JP 2015510944A JP 2015516412 A JP2015516412 A JP 2015516412A
Authority
JP
Japan
Prior art keywords
composition
formulation
pharmaceutically acceptable
aqueous
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510944A
Other languages
English (en)
Japanese (ja)
Inventor
アムセレム，シモン
ナヴェ，マイケル
Original Assignee
ペインリフォーム リミテッド
ペインリフォーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペインリフォーム リミテッド, ペインリフォーム リミテッド filed Critical ペインリフォーム リミテッド
Publication of JP2015516412A publication Critical patent/JP2015516412A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015510944A 2012-05-10 2013-05-09 局所麻酔薬のデポー製剤及びその調製方法 Pending JP2015516412A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261645066P 2012-05-10 2012-05-10
US61/645,066 2012-05-10
US201261649400P 2012-05-21 2012-05-21
US61/649,400 2012-05-21
US201361781625P 2013-03-14 2013-03-14
US201361781595P 2013-03-14 2013-03-14
US61/781,595 2013-03-14
US61/781,625 2013-03-14
PCT/IL2013/050410 WO2013168172A1 (en) 2012-05-10 2013-05-09 Depot formulations of a local anesthetic and methods for preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017193516A Division JP6574228B2 (ja) 2012-05-10 2017-10-03 局所麻酔薬のデポー製剤及びその調製方法

Publications (1)

Publication Number Publication Date
JP2015516412A true JP2015516412A (ja) 2015-06-11

Family

ID=49550270

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015510944A Pending JP2015516412A (ja) 2012-05-10 2013-05-09 局所麻酔薬のデポー製剤及びその調製方法
JP2015510942A Pending JP2015516411A (ja) 2012-05-10 2013-05-09 疎水性有効成分のデポー製剤及びその調製方法
JP2017193516A Active JP6574228B2 (ja) 2012-05-10 2017-10-03 局所麻酔薬のデポー製剤及びその調製方法
JP2017194260A Active JP6577548B2 (ja) 2012-05-10 2017-10-04 疎水性有効成分のデポー製剤及びその調製方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015510942A Pending JP2015516411A (ja) 2012-05-10 2013-05-09 疎水性有効成分のデポー製剤及びその調製方法
JP2017193516A Active JP6574228B2 (ja) 2012-05-10 2017-10-03 局所麻酔薬のデポー製剤及びその調製方法
JP2017194260A Active JP6577548B2 (ja) 2012-05-10 2017-10-04 疎水性有効成分のデポー製剤及びその調製方法

Country Status (9)

Country Link
US (3) US9668974B2 (enExample)
EP (2) EP2846773A4 (enExample)
JP (4) JP2015516412A (enExample)
CN (2) CN104427976B (enExample)
AU (2) AU2013257546B2 (enExample)
CA (2) CA2871820C (enExample)
IN (2) IN2014MN02213A (enExample)
RU (2) RU2664700C2 (enExample)
WO (2) WO2013168167A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547222A (ja) * 2021-01-14 2023-11-09 南京清普生物科技有限公司 徐放性製剤組成物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013257546B2 (en) * 2012-05-10 2017-12-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3331516B1 (en) * 2015-07-13 2024-08-14 Neon Laboratories Ltd. Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
EP3793536A1 (en) 2018-05-12 2021-03-24 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
JP7378929B2 (ja) * 2018-12-27 2023-11-14 花王株式会社 リポソームの製造方法
CN111388418B (zh) * 2018-12-31 2022-09-06 北京泰德制药股份有限公司 一种含有罗哌卡因或其药用盐的药物组合物
WO2020259670A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 一种缓释脂质组合物及其制备方法
US20230080811A1 (en) 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115463084B (zh) * 2021-06-10 2024-05-28 北京泰德制药股份有限公司 一种长效镇痛用复方油溶液制剂及其制备方法
AU2022346789A1 (en) * 2021-09-15 2024-03-28 Ocusoft, Inc. Ointments for treating dry skin
US20240065995A1 (en) * 2022-08-27 2024-02-29 Darren Alexander Rubin Injectable methods to treat deficiencies in glutathione metabolism and homocystinuria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513748A (ja) * 1998-04-30 2002-05-14 ユセベ，ソシエテ アノニム ゲル化性薬剤組成物
JP3571717B2 (ja) * 1991-10-04 2004-09-29 ゲー・エス・デイベロツプメント・アクチエボラーグ 粒子、該粒子の製法及びその使用
JP2007511525A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 注射可能な持続的な薬品送達ビヒクルとしての界面活性剤をベースとしたゲル
JP2008501676A (ja) * 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008502690A (ja) * 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252793A (en) 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
JPH0753661B2 (ja) 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US5173219A (en) 1986-02-12 1992-12-22 Research Development Foundation Uniform spherical multilamellar liposomes of defined and adjustable size distribution
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
NZ223660A (en) 1987-03-05 1990-11-27 Liposome Co Inc Low toxicity drug-lipid complexes; methods of making them; and method of determining their toxicity
CH681427A5 (enExample) 1987-07-01 1993-03-31 Zambon Spa
US5807572A (en) 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
EP0707472B1 (en) * 1993-07-08 2001-03-14 The Liposome Company, Inc. Method of controlling the size of liposomes
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
AU694147B2 (en) 1993-11-19 1998-07-16 Alkermes, Inc. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
CA2153553A1 (en) 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1997007794A1 (en) * 1995-08-28 1997-03-06 Showa Yakuhin Kako Co., Ltd. Composition for local anesthesia
ATE183092T1 (de) 1995-10-28 1999-08-15 Braun Melsungen Ag Lokalanästhetika und/oder zentralanalgetika enthaltende pharmazeutische zusammensetzungen
US5744337A (en) 1995-12-26 1998-04-28 The United States Of America As Represented By The Secretary Of The Navy Internal gelation method for forming multilayer microspheres and product thereof
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
ES2373861T3 (es) 1997-09-18 2012-02-09 Pacira Pharmaceuticals, Inc. Composiciones anestésicas liposomiales de liberación sostenida.
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7419683B2 (en) 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
ATE554748T1 (de) 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
IL140899A0 (en) 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
DK0982035T3 (da) * 1998-08-18 2004-06-28 Panacea Biotec Ltd Cyclosporinpræparater
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
EP1189597A4 (en) 1999-06-04 2008-06-18 Pacira Pharmaceuticals Inc COMPOSITIONS USING AN OIL CORE FOR DELAYED RELEASE HYDROPHOLE MEDICAMENTS
KR100343125B1 (ko) 1999-09-14 2002-07-05 임정옥 도포용 리포좀형 혼합국소마취제 및 그 제조방법
EP1138313A1 (de) 2000-03-28 2001-10-04 Primacare S.A. Pro-liposomen
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
JP2004532252A (ja) 2001-05-31 2004-10-21 スカイファーマ インコーポレーテッド リポソームおよびミクロスフェア中のナノ懸濁物のカプセル化
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US20030191093A1 (en) 2001-12-03 2003-10-09 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2481683A1 (en) 2002-04-10 2003-10-23 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20030236306A1 (en) 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2004024225A1 (en) 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
EP1551384A4 (en) 2002-10-07 2008-04-09 Encore Pharmaceuticals Inc R-NSAID ESTERS AND ITS USE
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050049209A1 (en) 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050186230A1 (en) 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
EP1729784A1 (en) 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
JP2008508302A (ja) 2004-07-28 2008-03-21 エスディー ファーマシューティカルズ インコーポレイティッド αコハク酸トコフェリル、そのアナログおよび塩の安定な注射用組成物
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
RU2008104638A (ru) 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) Фармацевтические композиции хорошо растворимых в воде лекарственных средств, обеспечивающих их замедленное высвобождение
US20070078434A1 (en) * 2005-09-30 2007-04-05 Vyteris, Inc. Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices
KR20080074201A (ko) 2005-12-02 2008-08-12 어드벤트륵스 파마슈티칼스, 인크. 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물
CN100563715C (zh) 2006-01-06 2009-12-02 中国药科大学 一种紫杉醇自组装前体脂质体及其制备方法
CN100486569C (zh) 2006-01-06 2009-05-13 中国药科大学 一种多烯紫杉醇自组装前体脂质体及其制备方法
CN100518738C (zh) 2006-01-06 2009-07-29 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP2107904A4 (en) * 2006-12-07 2010-06-02 Lyotropic Therapeutics Inc COMPOSITIONS FOR THE REVERSAL AND DETOXIFICATION OF NARCOSIVE EQUIPMENT AND OTHER COMPOUNDS AND METHOD OF USE
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008088756A1 (en) 2007-01-12 2008-07-24 Bridge Pharma, Inc. Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
ES2350029T3 (es) 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
WO2008114274A1 (en) * 2007-03-19 2008-09-25 Fresenius Kabi Onclology Ltd. Proliposomal and liposomal compositions
BRPI0704542B8 (pt) 2007-05-15 2021-05-25 Univ Estadual Campinas Unicamp composição farmacêutica, processo de obtenção da composição farmacêutica, uso de uma quantidade farmaceuticamente eficaz de anestésico e agente gelificante, produto e método de tratamento
RU2429242C2 (ru) 2007-05-30 2011-09-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Применение тетранитрозильного комплекса железа с тиофенолом в качестве противоопухолевого лекарственного средства
HUP0700426A2 (en) 2007-06-19 2010-03-29 Invencio 21 Gyogyhatasu Keszit Liposomal compound
CN101809024A (zh) 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
JP5608653B2 (ja) 2008-09-04 2014-10-15 ファーナム・カンパニーズ・インコーポレーテッド チュアブルな徐放性製剤
JP5753784B2 (ja) 2008-10-10 2015-07-22 ダラ・バイオサイエンシズ，インコーポレイテッド スピカマイシン誘導体を用いて疼痛を治療又は予防する方法
US20100305500A1 (en) 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
EP2470019A4 (en) 2009-08-25 2013-03-13 Cardiokine Biopharma Llc COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
EP2336286A1 (en) * 2009-12-18 2011-06-22 The Procter & Gamble Company Composition comprising microcapsules
WO2011096953A1 (en) 2010-02-05 2011-08-11 Cenerx Biopharma, Inc. Oral antidepressant formulation with reduced excipient load
WO2011121034A2 (en) 2010-04-01 2011-10-06 Pharmanest Ab Water-free pharmaceutical compositions suitable for local anaesthetics
EP3175844A1 (en) 2010-04-09 2017-06-07 Pacira Pharmaceuticals, Inc. Large diameter synthetic membrane vesicles
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2011153513A2 (en) 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k
CA2803004A1 (en) 2010-06-29 2012-01-12 Poniard Pharmaceuticals, Inc. Oral formulations of kinase inhibitors
EP2593089B1 (en) 2010-07-14 2018-04-04 Senju Pharmaceutical Co., Ltd. Solid dispersion of alfa-ketoamide derivative
BR112013003934A2 (pt) 2010-08-20 2016-06-07 Reddys Lab Ltd Dr depot de fosfolipídeos
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
KR101957177B1 (ko) 2010-10-22 2019-03-12 닥터 레디스 래보러토리즈 에스에이 상처를 치료하기 위한 저장 안정한 점성 인지질 데포의 용도
ES2770575T3 (es) 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
CN103826609A (zh) 2011-06-09 2014-05-28 安米林药品有限责任公司 凝胶组合物
AU2013257546B2 (en) * 2012-05-10 2017-12-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3571717B2 (ja) * 1991-10-04 2004-09-29 ゲー・エス・デイベロツプメント・アクチエボラーグ 粒子、該粒子の製法及びその使用
JP2002513748A (ja) * 1998-04-30 2002-05-14 ユセベ，ソシエテ アノニム ゲル化性薬剤組成物
JP2007511525A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 注射可能な持続的な薬品送達ビヒクルとしての界面活性剤をベースとしたゲル
JP2008501676A (ja) * 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008502690A (ja) * 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NETSU SOKUTEI, vol. 33(2), JPN6017001503, 2006, pages 74 - 82, ISSN: 0003483227 *
物性研究, vol. 68(3), JPN6017020612, 1997, pages 262 - 265, ISSN: 0003572807 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023547222A (ja) * 2021-01-14 2023-11-09 南京清普生物科技有限公司 徐放性製剤組成物
JP7627063B2 (ja) 2021-01-14 2025-02-05 南京清普生物科技有限公司 徐放性製剤組成物
AU2022208128B2 (en) * 2021-01-14 2025-02-06 Nanjing Delova Biotech Co. Ltd. Sustained-release preparation composition

Also Published As

Publication number Publication date
CA2871821A1 (en) 2013-11-14
CA2871820C (en) 2020-11-03
WO2013168167A1 (en) 2013-11-14
JP2015516411A (ja) 2015-06-11
CN104427976B (zh) 2018-04-24
CA2871820A1 (en) 2013-11-14
AU2013257608A1 (en) 2014-11-27
AU2013257608B2 (en) 2017-12-14
EP2846772A4 (en) 2015-12-30
IN2014MN02214A (enExample) 2015-07-17
RU2014144500A (ru) 2016-07-10
AU2013257546A1 (en) 2014-11-27
US20150111923A1 (en) 2015-04-23
RU2014144501A (ru) 2016-07-10
CN104427976A (zh) 2015-03-18
US20180049985A1 (en) 2018-02-22
JP6577548B2 (ja) 2019-09-18
EP2846773A4 (en) 2015-12-30
US9668974B2 (en) 2017-06-06
AU2013257546B2 (en) 2017-12-14
JP2017222729A (ja) 2017-12-21
JP2018035179A (ja) 2018-03-08
EP2846773A1 (en) 2015-03-18
CA2871821C (en) 2021-01-12
RU2664700C2 (ru) 2018-08-21
JP6574228B2 (ja) 2019-09-11
WO2013168172A1 (en) 2013-11-14
CN104427977B (zh) 2018-02-02
US20150148325A1 (en) 2015-05-28
CN104427977A (zh) 2015-03-18
IN2014MN02213A (enExample) 2015-07-10
RU2678433C2 (ru) 2019-01-29
US9849088B2 (en) 2017-12-26
US10206876B2 (en) 2019-02-19
EP2846772A1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
JP6574228B2 (ja) 局所麻酔薬のデポー製剤及びその調製方法
ES2514690T3 (es) Composiciones farmacéuticas de emulsión que comprenden progestógeno
CN108743952B (zh) 局部麻醉药的磷脂-混溶剂-油缓释递药系统组方与制备方法
TWI376239B (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP1765367A1 (en) Phospholipid compositions and methods for their preparation and use
CN117412743A (zh) 用于局部麻醉剂的乳剂
CN114344299A (zh) 一种具有长效缓释作用的脂质释药系统及其制备方法
AU2012275091B2 (en) Topical formulations including lipid microcapsule delivery vehicles and their uses
CN116669717A (zh) 长效原位成型/胶凝组合物
KR20140043250A (ko) 무복계면 칼슘 및 그 제조방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606